DR. RIMA MCLEOD, M.D.
Osteopathic Medicine at Maryland Ave, Chicago, IL

2005014, Jun 30, 2005

Apr 14, 2004

10/824194

Rima McLeod - Chicago IL, US
Craig Roberts - Glasgow, GB
Fiona Roberts - Glosgow, GB
Jennifer Johnson - Stillwater MN, US
Michael Kirisits - Chicago IL, US
David Ferguson - Tackley Oxford, GB
Russell Lyons - Glasgow, GB
Ernest Mui - Chicago IL, US
Doug Mack - Riverside IL, US
Benjamin Samuel - Chicago IL, US
Piotr Gornicki - Chicago IL, US
Ellen Zuther - Berlin, DE

A61K048/00, A01N063/00, A01H005/00

424093200

This invention relates uses of components of plant-like metabolic pathways not including psbA or PPi phosphofructokinase and not generally operative in animals or encoded by the plastid DNA, to develop compositions that interfere with Apicomplexan growth and survival. Components of the pathways include enzymes, transit peptides and nucleotide sequences encoding the enzymes and peptides, or promoters of these nucleotide sequences to which antibodies, antisense molecules and other inhibitors are directed. Diagnostic and therapeutic reagents and vaccines are developed based on the components and their inhibitors.

2013032, Dec 5, 2013

May 29, 2013

13/904063

Richard Delarey Wood - Washington Crossing PA, US
Rima McLeod - Chicago IL, US
Ernest Mui - Glasgow, GB
Alina Fomovska - New York NY, US
William Welsh - Princeton NJ, US

C07C 235/64, C07C 271/50, C07D 295/192

51425501, 514622, 514534, 514490

The present invention is directed to the method of use of effective pharmaceutical formulations for the treatment of diseases caused by apicomplexan parasites, said formulation comprised of a salicylanilide or salicylanilide derivative, disclosed herein, alone or in combination with one or more other active or excipient pharmaceutical substances. The present invention is further directed to the method of use of effective pharmaceutical formulations for the treatment of diseases caused by apicomplexan parasites, said formulation comprised of a combination of salicylanilides or salicylanilide derivatives, disclosed herein. The present invention is further directed to the method of use of effective pharmaceutical formulations for the treatment of diseases caused by apicomplexan parasites, said formulation comprised of a combination of salicylanilides or salicylanilide derivatives, disclosed herein, further comprised of one or more active or excipient pharmaceutical substances.

8575126, Nov 5, 2013

Jun 27, 2012

13/507427

Rima McLeod - Chicago IL, US
Bo Shiun Lai - Chicago IL, US
William Witola - Chicago IL, US
Kamal El Bissati - Chicago IL, US
Ernest Mui - Chicago IL, US
Hong Moulton - Corvallis OR, US
Jonathan B Rothbard - Menlo Park CA, US
Jon D Moulton - Corvallis OR, US

C12N 15/113, C07H 21/04

514 44A, 536 245

Pharmaceutical formulations of antisense peptide-conjugated phosphorodiamidate morpholino olgomers and methods of use for treatment of apicomplexan infections are disclosed. The invention is particularly directed to treatment of infections.

2003018, Oct 2, 2003

Oct 10, 2002

10/268611

Rima McLeod - Chicago IL, US
Michael Kirisits - Chicago IL, US
Craig Roberts - Kirklee, GB
Doug Mack - Centennial CO, US
Ernest Mui - Chicago IL, US
John Barnwell - Stone Mountain GA, US
John Dame - Gainesville FL, US
Jane Carlton - Rockville MD, US
Paul Bartlett - Oakland CA, US
Suzanna Parle - Seattle WA, US

C12Q001/18, C07H021/04, C12N001/10

435/032000, 435/258100, 536/023200

This invention relates uses of components of plant-like metabolic pathways not including psbA or PPi phosphofructokinase and not generally operative in animals or encoded by the plastid DNA, to develop compositions that interfere with Apicomplexan growth and survival. Components of the pathways include enzymes, transit peptides and nucleotide sequences encoding the enzymes and peptides, or promoters of these nucleotide sequences to which antibodies, antisense molecules and other inhibitors are directed. Diagnostic and therapeutic reagents and vaccines are developed based on the components and their inhibitors.

2004013, Jul 15, 2004

Jun 18, 2003

10/465527

Rima McLeod - Chicago IL, US
Stephen Muench - Stockport, GB
John Rafferty - Sheffield, GB
Dennis Kyle - , US
Ernest Mui - Chicago IL, US
Michael Kirisits - Chicago IL, US
Douglas Mack - Centennial CO, US
Craig Roberts - Glasgow, GB
Benjamin Samuel - Chicago IL, US
Russell Lyons - , US
Wilbur Milhous - Germantown MD, US
Sean Prigge - Severna Park MD, US
David Rice - Sheffield, GB

C12Q001/68, G01N033/53, G01N033/569, A61K031/05, C12N009/00

435/006000, 435/007220, 435/183000, 514/736000

Discovery and characterization of an apicomplexan Fab I gene and encoded enzyme and discovery of the triclosan as a lead compound, provide means to rationally design novel inhibitory compositions useful for prevention and treatment of apicomplexan related diseases.

2009015, Jun 18, 2009

Nov 5, 2007

11/998988

Rima McLeod - Chicago IL, US
Michael Kirisits - Ho Chi Minh City, VN
Dennis Kyle - Lithia FL, US
Douglas G. Mack - Centinnel CO, US
Wilbur Milhous - Tampa FL, US
Stephen Muench - Leeos, GB
Ernest J. Mui - Chicago IL, US
Sean Prigge - Severna Park MD, US
John Rafferty - Sheffield, GB
David Rice - Sheffield, GB
Craig W. Roberts - Glasgow, GB
Benjamin Samuel - Chicago IL, US

A61K 31/09, C12N 9/02, C07K 14/00, C12Q 1/26, C12Q 1/68, A61P 33/02

514717, 435189, 530350, 435 25, 435 6

Discovery and characterization of an apicomplexan Fab I gene and encoded enzyme and discovery of the triclosan as a lead compound, provide means to rationally design novel inhibitory compositions useful for prevention and treatment of apicomplexan related diseases.

2013027, Oct 17, 2013

Nov 3, 2011

13/823668

Rima McLeod - Chicago IL, US
Tze Guan Tan - Cambridge MA, US
Jeffery L. Alexander - San Diego CA, US
Hua Cong - Shandong, CN
William H. Witola - Auburn AL, US
Kamal El Bissati - Chicago IL, US
Ernest J. Mui - Chicago IL, US
Steven G. Reed - Bellevue WA, US

THE UNIVERSITY OF CHICAGO - Chicago IL
PAXVAX, INC. - San Diego CA
INFECTIOUS DISEASE RESEARCH INSTITUTE - Seattle WA

A61K 39/002

4241911

Vaccines are disclosed against parasites. The vaccines include peptides in an immunological composition. In particular, the parasite is